These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 10933152)

  • 1. Conversion from azathioprine [correction of azathioprina] to mycophenolate mofetil in pediatric renal transplant recipients with chronic rejection.
    Ferraris JR; Tambutti ML; Redal MA; Bustos D; Ramirez JA; Prigoshin N
    Transplantation; 2000 Jul; 70(2):297-301. PubMed ID: 10933152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
    Sollinger HW
    Transplantation; 1995 Aug; 60(3):225-32. PubMed ID: 7645033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
    Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: three-year follow-up. The Mycophenolate Mofetil Acute Renal Rejection Study Group.
    Mycophenolate Mofetil Acute Renal Rejection Study Group
    Transplantation; 2001 Apr; 71(8):1091-7. PubMed ID: 11374408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of mycophenolate mofetil on donor-specific antibody formation in renal transplantation.
    Lederer SR; Friedrich N; Banas B; Welser G; Albert ED; Sitter T
    Clin Transplant; 2005 Apr; 19(2):168-74. PubMed ID: 15740551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection.
    Theruvath TP; Saidman SL; Mauiyyedi S; Delmonico FL; Williams WW; Tolkoff-Rubin N; Collins AB; Colvin RB; Cosimi AB; Pascual M
    Transplantation; 2001 Jul; 72(1):77-83. PubMed ID: 11468538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients.
    Wagner M; Earley AK; Webster AC; Schmid CH; Balk EM; Uhlig K
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007746. PubMed ID: 26633102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclosporin withdrawal with concomitant conversion from azathioprine to mycophenolate mofetil in renal transplant recipients with chronic allograft nephropathy: a 2-year follow-up.
    Ducloux D; Motte G; Billerey C; Bresson-Vautrin C; Vautrin P; Rebibou JM; Saint-Hillier Y; Chalopin JM
    Transpl Int; 2002 Sep; 15(8):387-92. PubMed ID: 12221456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion from mycophenolate mofetil to azathioprine in high-risk renal allograft recipients on cyclosporine-based immunosuppression.
    Lou HX; Vathsala A
    Transplant Proc; 2004 Sep; 36(7):2090-1. PubMed ID: 15518756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: The Mycophenolate Mofetil Acute Renal Rejection Study Group.
    Transplantation; 1998 Jan; 65(2):235-41. PubMed ID: 9458021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, prospective trial of mycophenolate mofetil versus azathioprine for prevention of acute renal allograft rejection after simultaneous kidney-pancreas transplantation.
    Merion RM; Henry ML; Melzer JS; Sollinger HW; Sutherland DE; Taylor RJ
    Transplantation; 2000 Jul; 70(1):105-11. PubMed ID: 10919583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse effects of mycophenolate mofetil in pediatric renal transplant recipients with presumed chronic rejection.
    Butani L; Palmer J; Baluarte HJ; Polinsky MS
    Transplantation; 1999 Jul; 68(1):83-6. PubMed ID: 10428272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
    Vacher-Coponat H; Moal V; Indreies M; Purgus R; Loundou A; Burtey S; Brunet P; Moussi-Frances J; Daniel L; Dussol B; Berland Y
    Transplantation; 2012 Feb; 93(4):437-43. PubMed ID: 22228415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of a randomized, prospective, multicenter trial of mycophenolate mofetil versus azathioprine in the prevention of acute lung allograft rejection.
    Palmer SM; Baz MA; Sanders L; Miralles AP; Lawrence CM; Rea JB; Zander DS; Edwards LJ; Staples ED; Tapson VF; Davis RD
    Transplantation; 2001 Jun; 71(12):1772-6. PubMed ID: 11455257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A study comparing mycophenolate mofetil to azathioprine in simultaneous pancreas-kidney transplantation.
    Odorico JS; Pirsch JD; Knechtle SJ; D'Alessandro AM; Sollinger HW
    Transplantation; 1998 Dec; 66(12):1751-9. PubMed ID: 9884272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-center experience with mycophenolate mofetil in pediatric renal transplant recipients.
    Virji M; Carter JE; Lirenman DS
    Pediatr Transplant; 2001 Aug; 5(4):293-6. PubMed ID: 11472609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised open clinical trial of conversion from mycophenolate mofetil to azathioprine in cadaveric renal transplantation.
    Nowacka-Cieciura E; Kamiñska B; Cieciura T; Gradowska L; Pazik J; Lao M; Rowiñski W; Paczek L
    Transpl Int; 2000; 13 Suppl 1():S68-72. PubMed ID: 11111965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycophenolate mofetil reduces the risk of acute rejection less in African-American than in Caucasian kidney recipients.
    Schweitzer EJ; Yoon S; Fink J; Wiland A; Anderson L; Kuo PC; Lim JW; Johnson LB; Farney AC; Weir MR; Bartlett ST
    Transplantation; 1998 Jan; 65(2):242-8. PubMed ID: 9458022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced human IgG anti-ATGAM antibody formation in renal transplant recipients receiving mycophenolate mofetil.
    Kimball JA; Pescovitz MD; Book BK; Norman DJ
    Transplantation; 1995 Dec; 60(12):1379-83. PubMed ID: 8545860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycophenolate mofetil in pediatric renal transplantation.
    Otukesh H; Sharifian M; Basiri A; Simfroosh N; Hoseini R; Sedigh N; Golnari P; Rezai M; Fereshtenejad M
    Transplant Proc; 2005 Sep; 37(7):3012-5. PubMed ID: 16213289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.